Medical Device News Magazine

Biobeat Wearable Wrist and Chest Patient Monitoring Solutions Receives Class II Medical Device Approval from Health Canada

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

October 27, 2020

Biobeat provides wearable remote patient monitoring solutions for the healthcare continuum. Today they announced today that its wearable wrist and chest patient monitoring solutions have received Class II medical device approval (No. 320337) from Health Canada.

Biobeat reports their wireless wrist and chest monitoring solutions support health teams by transmitting real-time patient data from a distance, helping improve patient outcomes via accurate and reliable patient health updates and patient deterioration detection. These remote capabilities can be instrumental in helping monitor a variety of health conditions as well as mitigating the risk of infectious exposure, especially from COVID-19 patients.

“We are excited to receive the Health Canada Medical Device Class II approval, a significant milestone for our company, which will allow us to offer our innovative technologies to the Canadian healthcare market and help improve patient care,” said Arik Ben Ishay, CEO of Biobeat. “This registration underscores our mission to improve patient outcomes across the globe with our accurate wearable continuous patient monitoring solutions. We are eager to assist Canadian healthcare facilities and medical staff manage their patient workloads by using our advanced remote care abilities, especially during the current coronavirus pandemic.”

Maisha Labs, a Canadian digital health solution provider and integrator, assisted Biobeat throughout the licensing process and will continue to play a pivotal role in implementing the company’s solutions in healthcare facilities throughout the country. This includes an upcoming pilot project at The Jewish General Hospital and its Montreal-based Connected Health Futures Hub – OROT, orchestrated by a joint collaboration between Biobeat, Maisha Labs and the TransMedTech Institute, which will use Biobeat’s devices in a remote chronic care program.

Biobeat’s wearable wrist and chest-monitors utilize proprietary non-invasive reflective photoplethysmography monitoring technology to automatically and continuously track multiple vital signs and health parameters. The wireless solutions connect to a cloud-based patient management system to provide medical staff with real-time data and alerts, enabling early identification of clinical deterioration. The management platform includes an integrated automated, customizable early warning score system that incorporates advanced health-AI-based algorithms that analyze aggregated patient data to identify deterioration more accurately.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”